The stock of Venus Remedies opened with a gap up of 3.13% and touched an intraday high of Rs.702, representing an 8.67% rise during the trading session. This new peak marks both a 52-week and an all-time high for the company, reflecting strong market activity and investor focus on the stock. Over the past two days, Venus Remedies has recorded consecutive gains, delivering a cumulative return of 23.31% in this short span.
Trading above all key moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — the stock demonstrates robust technical strength. This upward trajectory is further highlighted by its outperformance relative to its sector, with Venus Remedies advancing 6.21% more than the Pharmaceuticals & Biotechnology sector today.
Over the last year, Venus Remedies has delivered a total return of 127.02%, significantly outpacing the Sensex’s 9.93% return during the same period. The stock’s 52-week low was recorded at Rs.272.20, illustrating the substantial appreciation in value over the past twelve months.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Venus Remedies’ financial metrics provide insight into the factors supporting this rally. The company reported a net profit after tax (PAT) of Rs.20.13 crores in the most recent quarter, reflecting a growth of 473.5%. This marks the fourth consecutive quarter of positive results, signalling consistent earnings momentum. The half-year return on capital employed (ROCE) stands at 13.99%, the highest recorded, while the inventory turnover ratio is at 6.58 times, indicating efficient management of stock levels.
Additionally, the company maintains a low debt-to-equity ratio averaging zero, underscoring a conservative capital structure. Its return on equity (ROE) is recorded at 10.5%, complemented by a price-to-book value of 1.5, suggesting an attractive valuation relative to its peers. The price-earnings-to-growth (PEG) ratio of 0.1 further reflects the company’s earnings growth in relation to its market price.
In the broader market context, the Sensex opened higher at 85,470.92 points, gaining 284.45 points or 0.33%, and reached a new 52-week high of 85,296.64 points during the session. The index is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a bullish market environment. Mega-cap stocks are leading the gains, with the Sensex registering a modest increase of 0.13% at the time of reporting.
Want to dive deeper on Venus Remedies ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Venus Remedies’ market capitalisation grade is rated 4, reflecting its standing within the Pharmaceuticals & Biotechnology sector. The stock’s recent performance has been marked by strong returns not only in the short term but also over the longer horizon. Over the past three years, the stock has outperformed the BSE500 index, reinforcing its position as a market-beating performer.
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund ownership may indicate a cautious stance or differing assessment of the stock’s valuation at current levels.
Overall, Venus Remedies’ achievement of a new 52-week high at Rs.702 highlights a period of significant momentum and positive financial results. The stock’s technical indicators, combined with strong earnings growth and efficient operational metrics, have contributed to this milestone within a broadly bullish market environment.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
